Analysts Predict $0.22 EPS for Hilton Worldwide Holdings Inc. in Q1

Brean Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Hilton Worldwide Holdings in a research report on Friday. (NYSE:HLT) a near short term price target of $33.08. The total amount of the transaction was worth $716,040, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing. Analysts at Goldman Sachs initiated coverage on shares of Zimmer Biomet Holdings in a research note on Wednesday, July 8th. Zacks lowered Hilton Worldwide Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, June 30th. Finally, analysts at Jefferies Group reiterated a “buy” rating and set a $127.00 price target (down previously from $131.00) on shares of Zimmer Biomet Holdings in a research note on Monday, May 11th.

Shares of Zimmer Biomet Holdings (NYSE:ZBH) have received a consensus rating of “Buy” from the nineteen analysts that are covering the company, AnalystRatingsNetwork.com reports.

The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. The stock presently has a consensus rating of “Buy” and an average price target of $31.39. The shares closed down 0.22 points or 0.81% at $26.83 with 12,074,220 shares getting traded. The company shares have rallied 6.3% in the past 52 Weeks. The higher price target estimate is at $35 while the lower price estimates are fixed at $28. The stock has a 50-day moving average of $110.31 and a 200-day moving average of $114.77. The company has a market cap of $26.49 billion and a P/E ratio of 37.79.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings data on Thursday, April 30th. Hilton, which also reported a better-than-expected quarterly profit on Wednesday, said its comparable revenue per available room (RevPAR) rose 5.2 per cent in the second quarter. The source also expects the hotel chain to report sales of $2.86 billion, missing the Street by $62 million. Post opening the session at $27.1, the shares hit an intraday low of $26.32 and an intraday high of $27.13 and the price vacillated in this range throughout the day. The company’s revenue for the quarter was up 10.0% on a year-over-year basis.

In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $0.85. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.